Healthcare

This study provides an overview of the global blood group typing industry, which is expected to witness significant growth, driven by factors like increased public awareness, improved healthcare infrastructure, government initiatives, and rising per capita income. The increasing prevalence of diseases associated with blood, such as sickle cell anem...

Home has become an attractive care delivery site because of the convenience, affordability, and patient-centric care environment it offers. The home care digitalization industry represents technologies that home care agencies use to improve/enhance services for the end user (B2B2C). The industry picked up pace during the COVID-19 pandemic and has s...

This analysis provides an overview and advancements in the oral solid dosage formulation industry, including an evaluation of the current industry scenario, competitive landscape, and regulatory landscape. The scope of the analysis is global, focusing on North America (NA), Europe, Asia-Pacific (APAC), the Middle East, and Latin America (LATAM). It...

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage. To understand the trend outlook fo...

The Global MedTech Outlook, 2024 presents a comprehensive analysis of the global MedTech industry in terms of growth potential and important market dynamics. The analysis covers major MedTech segments such as cardiovascular, orthopedics, patient monitoring, respiratory devices, neurology, diabetes care, and clinical-grade wearables. It highlights k...

In this analysis, Frost & Sullivan covers the heart valves industry, including aortic, mitral, tricuspid, and pulmonary valves. We address critical questions such as market sizes, growth rates, opportunities, strategic imperatives, technology impact, and untapped potential in the industry. Our analysis shows that the industry is gaining traction...

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essen...